Adam Gazzaley on Experiential Medicine

From Brain Mind 2023 at UCSF.

“We have a cognition crisis. And we are in a renaissance of experimental medicine because of technology like digital therapeutics. It makes medicine a personal, scalable, testable and closed-loop experience. Only experiences activate certain networks in the brain; no drug does it. With Akili, we received FDA approval for a video game as a de novo class 2 treatment for ADHD. It took many years, but then we learned that the big barrier is insurance reimbursement. There is a 5-year delay, on average, from FDA approval to insurance reimbursement.”